IGI Logo
Toggle Navigation
News
Hindi
Hindi News
Top News
Screeners
Stocks
Stocks Screener
Stock
News
Stock Market Home Page
Stock News
Industry News
Economy News
Stock on the move
Expert Views
Research Reports
Company Result
Comp Info And Fundamentals
Company Profile
Equity
Financial Ratios
Results
Balance Sheet
Profit And Loss
Cash Flow
Share Holding
Derivatives (F&O)
Get Quotes
Market Watch
Top Gainers
Top Losers
Top Traded Quantity
Top Traded Value
Most Active Puts
Derivatives (F&O)
Most Active Calls
Put Call Ratio
Highest In Premium
Daily Settlement Price
FII and DII Statistics
Open Interest: Highest In OI
Open Interest: Lowest In OI
Derivatives (F&O)
Open Interest: Increase in OI Increase in Price
Open Interest: Decline in OI Decrease in Price
Derivative Watch
Derivatives Dashboard
Historical Data
List of Underlyings & Underlying Info
Derivative Watch
Derivatives Dashboard
Market Reports
Top Gainers
Top Losers
Monthly High/Low
52 Week High
52 Week Low
Market Cap Gainers
Market Cap Losers
PE Ratio
>More Market Reports
IPO
News
IPO News
IPO Issue Reports
Commodity
Commodity Market
Commodity Home Page
Commodity News
Commodity Reports
Market Details
Get Quotes
Top Gainers
Top Losers
Top Volume
Top Value
Top Gainers Spot Market
Top Losers Spot Market
High & Low
Commodity Indices
Technical Analysis
Advance Declines
High & Low
Highest In OI
Lowest OI
Increase In Open Interest(%)
Descrease In Open Interest(%)
Currency
News
Currency News
Economy News
Currency Reports
Mutual Fund
News
Mutual Fund Home Page
Mutual Fund News
Mutual Fund Details
Mutual Fund Home Page
Compare Scheme
Scheme Profile
Mutual fund Investment
Mutual Fund Share Holding
Mutual Fund Statistics
Mutual fund Gainers
Mutual fund Losers
Biggest Schemes
Best Performers
Latest Dividend Details
Tools
Multi Scheme Comparison Tool
Dividend Details
Performance Map
Mutual fund Investment
Mutual fund Share Holding
Mutual Fund Search Category Rankings
Widgets
Stock Widgets
Watchlist
Heatmap
Mutual Fund Widgets
Watchlist
Calculators
EMI Calculator
SIP Calculator
SWP Calculator
GST Calculator
FD Calculator
RD Calculator
Wealth
World
Tips
Intraday Tips
Market Outlook
Stock Tips
Commodity Tips
Currency Tips
Reports
Short Term Investment Opportunities
Long Term Investment Opportunities
Sector Analysis
Commodity Reports
Currency Reports
Mutual Fund Analysis
Podcast
Videos
Videos Category
Business Videos
Budget Videos
News And Politics
Entertainment Videos
Sports Videos
Lifestyle And Fashion Videos
Global News Videos
Calculators
EMI Calculator
SIP Calculator
SWP Calculator
GST Calculator
FD Calculator
RD Calculator
More
Budget 2024
Astrology
Women
Politics
Entertainment
Car&Bike
Gadgets
Lifestyle
Sports
Health
Fashion
Diwali Reports
Diwali Expert Reports
News
Astrology
Beyond Market Car
Beyond Market Entertainment
Beyond Market Fashion
Beyond Market Gadgets
Beyond Market Health
Beyond Market India
Beyond Market Life Style
Beyond Market Sports
Broking Firm Views
Broking Firm Views - Long Term Report
Broking Firm Views - Sector Report
Broking Firm Views - Short Term Report
Budget 2024 Sector Reports
Budget Bites
Budget Economic Servey
Budget Expert Views
Budget Industry
Budget News
Budget Wishlist
Commodities
Commodities Reports
Commodity Top News
Company News
Company Result
Currency News
Currency Report
Currency Top News
Diwali Expert Views
Diwali Market Outlook
Diwali Report
Diwali Technical Report
Economy News
Expert View Institution
Expert Views
Industry News
IPO Analysis
IPO More News
IPO Reports
IPO Top News
Market Outlook
Mutual Fund Analysis
Mutual Fund Expert Views
Mutual Fund More News
Mutual Fund Top News
Podcast - Market Ki Awaaz
Special Event Expert Views
Special Event Reports
Startup
Startup Expections
Startup Speak
Stock Market
Stock On The Move
Top News
Top Stories
Videos
Videos Business
Videos Entertainment
Videos Global News
Videos Lifestyle And Fashion
Videos News And Politics
Videos Sports
Wealth
Women
World Market More News
World Top News
Search
Eli Lilly and Company announced on Monday that it has issued an additional royalty-free, non-exclusive voluntary license to Natco Pharma; a local pharmaceutical manufacturer of generic medicines. Under the terms of the license, Natco will be collaborating with Lilly to further accelerate and expand the availability of baricitinib in India during this pandemic, improving the local treatment options available to people who are currently battling Covid-19 in India. Lilly received permissio...
Lilly signs an Additional Voluntary Licensing Agreement on Baricitinib
Eli Lilly and Company on Thursday announced that it has issued additional royalty-free, non-exclusive voluntary licenses to the Indian pharmaceutical manufacturers of generic medicines, Dr. Reddy's Ltd, MSN Laboratories and Torrent Pharmaceuticals, who will be collaborating to accelerate and expand the availability of baricitinib for Covid treatment in India. These three additional voluntary licensing agreements will ensure high quality manufacturing and accessibility of baricitinib du...
Lilly inks three new pacts to expand availability of baricitinib drug
MSN Labs (MSN) on Thursday announced it has entered into a royalty free, non-exclusive, voluntary license agreement with Eli Lilly and Company of USA for manufacturing and marketing of baricitinib for Covid-19 in India. The drug baricitinib has been granted a restricted emergency use approval in India by the Central Drugs Standard Control Organization for emergency use in combination with remdesivir for the treatment of suspected or laboratory confirmed Covid-19 in hospitalised adults requ...
MSN Labs inks deal with Lilly to launch baricitinib
Eli Lilly announced that it has issued royalty-free, non-exclusive voluntary licenses to Indian pharmaceutical manufacturers of generic medicines, Cipla Ltd., Lupin Ltd. and Sun Pharmaceutical Industries Ltd., who are collaborating with Lilly to accelerate and expand the availability of baricitinib in India. Lilly is also in discussions with several other Indian manufacturers for the potential grant of additional voluntary licenses. These voluntary licensing agreements will ensure...
Eli Lilly signs agreements with Cipla, Lupin and Sun Pharma
BENGALURU -Eli Lilly and Co said on Monday it had signed licensing agreements with three Indian generic drugmakers to expand the availability of its arthritis drug baricitinib in the country for treating COVID-19 patients. The agreements will bolster India's arsenal of drugs to battle its catastrophic second wave of the pandemic, which has led to an acute shortage of coronavirus medicines including remdesivir and tocilizumab. The three Indian drugmakers - Cipla Ltd, Lupin Ltd ...
Eli Lilly signs deals to boost supply of COVID-19 treatment in India
BENGALURU-Indian drugmaker Cipla Ltd said on Monday it had entered into a licensing agreement with U.S. company Eli Lilly and Co to make and sell Lilly's arthritis drug baricitinib for the treatment of COVID-19 patients. The agreement comes at a time when India is struggling with a catastrophic second wave of the pandemic, leading to an acute shortage of coronavirus medicines such as remdesivir and tocilizumab. Baricitinib has been given restricted emergency use approval by India...
India`s Cipla to make and sell Eli Lilly`s baricitinib to treat COVID-19
Eli Lilly & Co employees have accused a factory executive of altering documents required by government regulators in an effort to downplay serious quality control problems at the U.S. plant producing the drugmaker’s COVID-19 treatment, according to an internal Lilly complaint and a source familiar with the matter. The unsigned report, filed April 8 in Lilly’s confidential employee complaint system and reviewed by Reuters, is the latest sign of manufacturing problems at the ...
Lilly hit by staff accusations, FDA scrutiny at COVID drug factories
Eli Lilly and Co said on Tuesday it would make an immediate initial donation of 400,000 tablets of its COVID-19 treatment to the Indian government for eligible hospitalized COVID-19 patients.
Eli Lilly to donate 400,000 tablets of its COVID-19 treatment to India
Eli Lilly and Co on Tuesday missed expectations for first-quarter profit and cut the top end of its full-year earnings forecast as demand waned for its COVID-19 antibody therapies with the U.S. vaccine rollout in full swing. Nearly 30% of the U.S. population has been vaccinated against COVID-19, hitting demand for antibody drugs that already suffered from slower-than-expected uptake by hospitals. "We didn't get into this thinking about margins. We wanted to be useful during the...
Eli Lilly profit forecast trimmed as vaccines dent U.S. demand for COVID-19 drugs
Indian-Canadian comedian Lilly Singh has credited Hollywood star Drew Barrymore for becoming the person she is today. Singh made the revelation when Barrymore told her she liked the fact that Lilly was "self-aware and astute to make the kind of call to do a whole new show from the very comfort of your home". The Hollywood star was talking about Lilly's popular show. Barrymore added: "I was so excited to talk with you because as a woman who loves comedy, you were break...
Lilly Singh reveals how Drew Barrymore inspired her
Eli Lilly and Co on Saturday said its experimental Alzheimer’s drug slowed the rate of decline in a measure of cognition and function by 32% compared with a placebo in a mid-stage trial of patients at an early stage of the mind wasting disease. The drug, donanemab, also showed positive trends that failed to reach statistical significance on a range of secondary trial goals, the company said, providing details for the first time. The 18-month, 272-patient study showed, for instance...
Lilly Alzheimer's drug shows benefit on cognition, function in mid-stage trial
Load More